Antiobesogenic effects of central GIPR antagonism
Jessica T.Y. Yue1 and Tony K.T. Lam2,3,4,5
1Department of Physiology, University of Alberta, Edmonton, Alberta, Canada.
2Toronto General Hospital Research Institute, University Health Network (UHN), Toronto, Ontario, Canada.
3Department of Physiology,
4Department of Medicine, and
5Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada.
Address correspondence to: Jessica Yue, 7-21 Medical Sciences Building, Department of Physiology, University of Alberta, Edmonton, Alberta, Canada T6G2H7. Phone: 780.248.5804; Email: jessica.yue@ualberta.ca. Or to: Tony Lam, MaRS Centre, 101 College Street, Toronto Medical Discovery Tower, 10th floor, Room 705, Toronto, Ontario, Canada M5G1L7. Phone: 416.581.7880; Email: tony.lam@uhnres.utoronto.ca.
Find articles by Yue, J. in: JCI | PubMed | Google Scholar
1Department of Physiology, University of Alberta, Edmonton, Alberta, Canada.
2Toronto General Hospital Research Institute, University Health Network (UHN), Toronto, Ontario, Canada.
3Department of Physiology,
4Department of Medicine, and
5Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada.
Address correspondence to: Jessica Yue, 7-21 Medical Sciences Building, Department of Physiology, University of Alberta, Edmonton, Alberta, Canada T6G2H7. Phone: 780.248.5804; Email: jessica.yue@ualberta.ca. Or to: Tony Lam, MaRS Centre, 101 College Street, Toronto Medical Discovery Tower, 10th floor, Room 705, Toronto, Ontario, Canada M5G1L7. Phone: 416.581.7880; Email: tony.lam@uhnres.utoronto.ca.
Find articles by Lam, T. in: JCI | PubMed | Google Scholar
First published August 12, 2019 - More info
J Clin Invest. 2019;129(9):3532–3535. https://doi.org/10.1172/JCI130755.
© 2019 American Society for Clinical Investigation
Developing effective treatments for obesity and related metabolic disease remains a challenge. One logical strategy targets the appetite-regulating actions of gut hormones such as incretins. One of these incretins, glucose-dependent insulinotropic polypeptide (GIP), has garnered much attention as a potential target: however, whether it is beneficial to boost or block the action of GIP to promote weight loss remains an unresolved question. In this issue of the JCI, Kaneko and colleagues show that antagonizing GIP signaling in the CNS enhances the weight-reducing effects of leptin in rodents with diet-induced obesity. The authors posit that an increase in circulating intestinally derived GIP, as a consequence of overnutrition, acts in the brain to impair hypothalamic leptin action, resulting in increased food intake and body weight gain. This research advances the idea that multiple GIP signaling pathways and mechanisms exist in the obese state and offers intriguing insights into the antiobesogenic consequences of antagonizing brain GIP action.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)